Health and Healthcare
Dendreon Gives Quarterly Report & Provenge Updates (DNDN)
Published:
Last Updated:
Dendreon Corp. (NASDAQ: DNDN) has its quarterly results out, although it is via SEC Filing rather than via a press release. We had this on deck for a report this week and a conference call was set for Tuesday at 11:30 AM EST.
Dendreon’s total operating expenses were $20.929 million and net loss after items of $126.7 million after a $105+ million warrant item. That is not just from operations and it does include many ongoing or new items. That comes to a loss of $1.20 EPS and revenues were listed as $25,000.00.
More importantly, the company disclosed its expansion facilities and the associated costs in Georgia and in California. Dendreon is still expecting PROVENGE to be approved and it gave updates along those lines.
FULL DETAILS of the financial data and updates on Provenge are at BioHealthInvestor.com.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
